The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: A systematic review

Judith Bosschieter; Catrin Lutz; Loes I. Segerink; André N. Vis; Ellen C. Zwarthoff; R. Jeroen A. van Moorselaar; Bas W.G. van Rhijn; Martijn W. Heymans; Elizabeth P. Jansma; Renske D.M. Steenbergen; Jakko A. Nieuwenhuijzen

doi:10.2217/epi-2017-0156

The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: A systematic review

Judith Bosschieter
, Catrin Lutz
, Loes I. Segerink
, André N. Vis
, Ellen C. Zwarthoff
, R. Jeroen A. van Moorselaar
, Bas W.G. van Rhijn
, Martijn W. Heymans
, Elizabeth P. Jansma
, Renske D.M. Steenbergen
, Jakko A. Nieuwenhuijzen^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Review article › Academic › peer-review

31 Citations (Scopus)

52 Downloads (Pure)

Abstract

Aim: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.

Patients & methods: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.

Results: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.

Conclusion: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

Original language	English
Pages (from-to)	673-687
Number of pages	15
Journal	Epigenomics
Volume	10
Issue number	5
DOIs	https://doi.org/10.2217/epi-2017-0156
Publication status	Published - 1 May 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

2019 OA procedure
Molecular diagnostics
Neoplasms
Urinary bladder
Urine analysis
Biomarkers
Methylation

Access to Document

10.2217/epi-2017-0156

ArticleFinal published version, 1.4 MBLicence: Taverne

Cite this

Bosschieter, J., Lutz, C., Segerink, L. I., Vis, A. N., Zwarthoff, E. C., van Moorselaar, R. J. A., van Rhijn, B. W. G., Heymans, M. W., Jansma, E. P., Steenbergen, R. D. M., & Nieuwenhuijzen, J. A. (2018). The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: A systematic review. Epigenomics, 10(5), 673-687. https://doi.org/10.2217/epi-2017-0156

@article{d18579f4a5394fb3a7fcab1402afde79,

title = "The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: A systematic review",

abstract = "Aim: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.Patients \& methods: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.Results: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100\%) and specificities (0-100\%). Considerable heterogeneity across studies was observed and most was case-control studies.Conclusion: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.",

keywords = "2019 OA procedure, Molecular diagnostics, Neoplasms, Urinary bladder, Urine analysis, Biomarkers, Methylation",

author = "Judith Bosschieter and Catrin Lutz and Segerink, \{Loes I.\} and Vis, \{Andr{\'e} N.\} and Zwarthoff, \{Ellen C.\} and \{van Moorselaar\}, \{R. Jeroen A.\} and \{van Rhijn\}, \{Bas W.G.\} and Heymans, \{Martijn W.\} and Jansma, \{Elizabeth P.\} and Steenbergen, \{Renske D.M.\} and Nieuwenhuijzen, \{Jakko A.\}",

year = "2018",

month = may,

day = "1",

doi = "10.2217/epi-2017-0156",

language = "English",

volume = "10",

pages = "673--687",

journal = "Epigenomics",

issn = "1750-1911",

publisher = "Taylor \& Francis",

number = "5",

}

TY - JOUR

T1 - The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer

T2 - A systematic review

AU - Bosschieter, Judith

AU - Lutz, Catrin

AU - Segerink, Loes I.

AU - Vis, André N.

AU - Zwarthoff, Ellen C.

AU - van Moorselaar, R. Jeroen A.

AU - van Rhijn, Bas W.G.

AU - Heymans, Martijn W.

AU - Jansma, Elizabeth P.

AU - Steenbergen, Renske D.M.

AU - Nieuwenhuijzen, Jakko A.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Aim: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.Patients & methods: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.Results: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.Conclusion: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

AB - Aim: Several urinary hypermethylation-markers (hmDNA) have been described for bladder cancer (BC) detection, but none have been able to replace cystoscopy yet. We systematically reviewed and evaluated current literature on urinary hmDNA markers for BC diagnostics.Patients & methods: A systematic search of PubMed, EMBASE.com and The Cochrane Library up to February 2017 using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, was conducted.Results: A total of 30/42 studies included compared gene panels, with varying sensitivities (52-100%) and specificities (0-100%). Considerable heterogeneity across studies was observed and most was case-control studies.Conclusion: Reported diagnostic accuracy of urinary hmDNA for BC detection is highly variable and there is a lack of validation studies. Recent studies indicate that complementary markers are needed to allow for clinical implementation.

KW - 2019 OA procedure

KW - Molecular diagnostics

KW - Neoplasms

KW - Urinary bladder

KW - Urine analysis

KW - Biomarkers

KW - Methylation

UR - https://www.scopus.com/pages/publications/85047120656

U2 - 10.2217/epi-2017-0156

DO - 10.2217/epi-2017-0156

M3 - Review article

AN - SCOPUS:85047120656

SN - 1750-1911

VL - 10

SP - 673

EP - 687

JO - Epigenomics

JF - Epigenomics

IS - 5

ER -

The diagnostic accuracy of methylation markers in urine for the detection of bladder cancer: A systematic review

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this